

Announcements for this section should be submitted in the correct format at least 3 months before the required date of publication. This list is provided as a service to readers; inclusion does not imply endorsement by the Hepatobiliary & Pancreatic Diseases International.

Section editor

Shui-Ying Lei

Email: hbpdint@126.com

March, 2019

EASL/AASLD HBV treatment endpoints workshop March 8-9, 2019; London, United Kingdom

The purpose of this workshop is to bring together the academic, regulatory and pharmaceutical (diagnostic and therapeutic) communities to discuss therapeutic endpoints, trial designs, appropriate patient populations and safety concerns with regards to novel therapeutic approaches aimed to achieve HBV cure. This meeting will bring all the stakeholders together to discuss definitions of HBV cure, likelihood of HBV cure with currently approved therapies, preclinical and clinical data on novel antiviral and immune modulatory therapies, appropriate designs and endpoints for trials to evaluate therapies aimed at HBV and HDV cure, and strategies to efficiently and safely evaluate combination therapies. These discussions will provide guidance regarding potential pathways leading to regulatory approval of therapies that will result in high rates of HBV cure in individuals with chronic hepatitis B and chronic hepatitis D. For more information, please visit: <https://www.aasld.org/events-professional-development/easl-aasld-hbv-treatment-endpoints-workshop>.

TASL-AASLD hepatology connect March 15-16, 2019; Istanbul, Turkey

AASLD and the Turkish Association for the Study of the Liver (TASL) announce an inaugural joint conference to connect physicians and health care providers in Turkey and the surrounding region with experts in hepatology. The connect program is designed to deliver a state-of-the-art scientific program by bringing world renowned experts to the meeting. We are pleased to present AASLD and TASL speakers in six important areas of hepatology today, including viral hepatitis B, C, and D, non-alcoholic fatty liver disease, cirrhosis and liver transplantation and hepatocellular carcinoma. The connect program's format consists of review of the standard guidelines for these conditions followed by discussion of the latest data as well as application of those new data in the loco-regional practice. In this event, we also feature a Rising Star Symposium to help develop academic skills for young hepatologists. For more information, please visit: <http://www.taslaasld-istanbul2019.org/>.

Emerging topic conference: Advances in HCC therapies and trial design March 22-23, 2019; the Westin Buckhead Atlanta, Atlanta, GA, USA

Program chairs are Profs. Josep M. Llovet, MD, PhD, FAASLD and Lewis R. Roberts, MBChB, PhD, FAASLD. The Emerging trends

conference will provide the opportunity for attendees to learn more about and improve upon their selection of precise therapy for patients with hepatocellular carcinoma. Also, attendees will increase their knowledge regarding design, implementation and participation in HCC clinical trials with an enhanced ability to assess the efficacy of treatment using a variety of response criteria. Learning objectives include: 1) To review novel strategies for biomarker based clinical trial designs and articulate new approaches including the role of tumor biopsies and circulating cell-free based assays in guiding therapeutic decision-making; 2) To understand recent advances in integrated molecular classification of HCC and their application to improved treatment of HCC; and 3) To review recently approved molecular therapies and anticipated novel immune-based, cellular, and oncolytic virus therapies for HCC and effectively manage the common side effects of these therapies. For more information, please visit: <https://www.aasld.org/events-professional-development/emerging-topic-conference-advances-hcc-therapies-and-trial-design>.

CSCO-AACR joint conference on immunotherapy March 22-23, 2019; Marriott Shanghai Parkview Hotel, Shanghai, China

The CSCO-AACR joint conference is to be held on March 22-23, 2019, in Shanghai, China. The program will bring together researchers from the United State, China, and around the world to share the latest developments focusing on translational to clinical applications of immunotherapy with an emphasis on cancers with high incidence in the region. Each session will feature speakers from both China and abroad and offer ample opportunity to foster international scientific exchange. For more information, please visit: <https://www.aacr.org/Meetings/Pages/MeetingDetail.aspx?EventItemID=177>.

AASLD-CFHPC hepatology connect March 22-24, 2019; Beijing, China

The American Association for the Study of Liver Diseases (AASLD) and the Chinese Foundation for Hepatitis Prevention and Control (CFHPC) announce an inaugural joint conference to connect physicians and health care providers in China with experts in hepatology. This program will offer a unique opportunity to exchange knowledge and ideas, to foster collaborative research between Chinese and American physicians, surgeons and researchers, and to train the next generation of researchers in China. The program will include presentations of the latest research data but also clinical case discussions, lectures on how to conduct research and feedback on research presentations. For more information, please visit: <http://achcc2019.medmeeting.org/Content/111373>.

AACR annual meeting 2019
March 29-April 3, 2019; Georgia World Congress
Center, Atlanta, Georgia, USA

Program committee chair is Prof. John D. Carpten, USC Keck School of Medicine, Los Angeles, California. The AACR annual meeting program covers the latest discoveries across the spectrum of cancer research—from population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy—and highlights the work of the best minds in research and medicine from institutions all over the world. For more information, please visit: <https://www.aacr.org/Meetings/Pages/MeetingDetail.aspx?EventItemID=174>.

April
European specialty examination in gastroenterology
and hepatology (ESEGH)
April 10, 2019; Montijo, Portugal

The ESEGH is a pan-European knowledge-based assessment for Gastroenterology and Hepatology trainees, delivered in partnership with the Federation of Royal Colleges of Physicians of the UK (Federation) and the British Society of Gastroenterology (BSG), based on the successful EBGH Examination and the Specialty Certificate Examination (SCE) in Gastroenterology. The ESEGH is a high quality, reliable examination, based on a proven format, now UK (General Medical Council) Regulator approved, which is currently mandatory in the Netherlands, Switzerland and the UK from 2018. For more information, please visit: <http://www.easl.eu/discover/events/detail/2019/european-specialty-examination-in-gastroenterology-and-hepatology-esegh-1>.

The international liver congress™ 2019
April 10-14, 2019; Vienna, Austria

The international liver congress™ 2019 will take place on April 10-14, 2019, Vienna, Austria, which is the annual EASL meeting and the flagship event in EASL's educational calendar. Scientific and medical experts from a broad range of fields including hepatology, gastroenterology, internal medicine, cell biology, transplant surgery, infectious diseases, microbiology and virology, pharmacology, pathology and radiology and imaging come together from around the world to learn about the latest in liver research. Specialists share recent data, present studies, and findings, and discuss the hottest topics on liver disease. The annual congress attracted over 10 000 delegates and 250 media representatives from all over the world making this a truly international networking opportunity. For more information, please visit: <http://www.easl.eu/discover/events/international-liver-congress>.

Infectious diseases in adults 2019
April 23-27, 2019; Boston, United States

This comprehensive Harvard Medical School CME program—one of the highest-rated HMS CME courses—ensures attendees are current with state-of-the-art approaches to prevention, detection, diagnosis and treatment of infectious diseases. Updates, best practices and

new guidelines are presented by nationally recognized ID experts and master clinicians. Education is practical and results driven: 1) Strategies for optimal decision-making in the prevention, diagnosis and treatment of infectious diseases; 2) Newer antimicrobials and treatment strategies for highly resistant bacterial infections; 3) State-of-the-art approaches to common infections; 4) Clinical approaches to complex, rare, “don't-miss” infections; 5) New and emerging infectious diseases; 6) Update on antifungal diagnostics and therapy; 7) Optimal management of Staph aureus infections (MSSA and MRSA); 8) Infections in persons with substance use disorders; 9) What's new in HIV management and prevention; 10) Hep C treatment workshop (optional); and 11) Musculoskeletal infectious diseases. For more information, please visit: <https://id.hmscme.com/>.

May
Modern dilemmas in liver transplantation
May 2-3, 2019; Edgbaston, United Kingdom

Through a series of six cases, the school will highlight and discuss in detail some of the complicated nuances in the management of the modern liver transplant recipient throughout their journey from assessment, to the transplant procedure itself and then the immediate and long term management of the patients. Particular emphasis will be given to areas of uncertainty and the expert multidisciplinary faculty will be on hand to provide their personal experiences and opinions on these cases. Target audiences are: 1) Hepatologists in training especially those considering a career in adult liver transplantation; 2) Transplant surgeons in training; 3) Intensive care trainees with an interest in management of liver transplant patients; and 4) Liver transplant coordinators or other multidisciplinary professionals working in the liver transplant field. The learning objectives are: 1) To gain knowledge of the transplant assessment process and understand how cumulative risks are assessed prior to listing patients for liver transplant; 2) To understand the criteria for transplantation in HCC and how different modalities can be used to bridge and/or downstage patients; 3) To gain an understanding of the increasing availability and utilization of machine perfusion in liver transplantation and how this impacts on both donor and recipient choice; 4) To start to appreciate the complexities of management of the transplant recipient on the intensive care unit in the immediate aftermath of the operation; 5) To gain a good working knowledge of the different immunosuppressive regimens used post transplant and the impact of rejection and recurrent disease on the recipient; 6) To understand the incidence and impact of hepatic artery thrombosis on transplant recipients and how this condition should be managed; and 7) To start to appreciate the unique challenges involved in management of adolescent and young adult recipients of liver transplants. For more information, please visit: <http://www.easl.eu/discover/events/detail/2019/modern-dilemmas-in-liver-transplantation>.

AASLD/FDA DILI conference
May 7-8, 2019; College Park Marriott Hotel and
Convention Center, Hyattsville, USA

Program chairs are Mark I. Avigan, MD, CM and Robert J. Fontana, MD, FAASLD. This international academic-industry-government conference sponsored by the FDA and AASLD, will hear expert presentations on new treatments with hepatotoxic liability and discuss study populations of growing concern as well as many state-of-the-art

scientific tools and methods that are now becoming available for the assessment of DILI risk. There will also be a robust exchange of ideas and debate towards establishing consensus among participants in the meeting as a prelude for a planned comprehensive revision of the seminal FDA guidance on the pre-marketing evaluation of DILI. Learning objectives are: 1) To understand the means by which a diagnosis of DILI is established and the value and limitations of causality instruments, severity scales, liver histology and available diagnostic/prognostic biomarkers; 2) How to assess DILI diagnosis and severity in patients with pre-existing liver disease; 3) How to diagnose and manage patients who experience liver injury while receiving investigational immunotherapy for benign and malignant diseases. For more information, please visit: <https://www.aasld.org/events-professional-development/aasld-fda-dili-conference>.

Digestive disease week (DDW) May 18-21, 2019;

DDW is co-sponsored by AASLD, AGA, ASGE and SSAT. The AASLD meeting at DDW provides a forum for the exchange of groundbreaking research and clinical information in diseases of the liver and biliary tract and in liver transplantation, including plenary and parallel sessions, courses, workshops and state-of-the-art lectures. For more information, please visit: <https://www.aasld.org/events-professional-development/digestive-disease-week-0>.

2019 ILTS annual congress May 15-18, 2019; Toronto, Canada

ILTS 2019 will be held on May 15-18, 2019, in Toronto, Canada. The goal of this Congress is to broaden the education of scientists, surgeons, anesthesiologists, hepatologists, radiologists, pathologists, nurses, and organ procurement personnel in the latest advances in the care and treatment of liver transplant patients. For more information, please visit: 2019.ilsts.org.

Metabolism, immunity and liver disease May 16-18, 2019; Munich, Germany

“Metabolic inflammation, immunity and liver disease” will take place at the TUM School of Medicine University Hospital rechts

der Isar from May 16-18, 2019. The EASL school on “Metabolic inflammation, immunity and liver disease” will invite key experts of the field, develop a thorough understanding of key and cutting edge technologies, engage in discussion about the burning scientific questions and current as well as new developments in the field. Excellent scientists from the fields of metabolism, liver immunology, NASH, viral hepatitis, microbiome and proteome research form an outstanding faculty for attendees to engage in a lively discussion embedded in a hearty Bavarian atmosphere. Learning objectives include: 1) To understand the challenges in liver diseases associated with metabolism and inflammation; 2) To learn research-based skills in cutting edge technologies used in the evaluation of metabolism at the cellular and organ/systemic level, of the immune pathogenesis of metabolism-associated disease, immune monitoring and cutting-edge non-invasive imaging to acquire competence in conducting research on liver disease; 3) To learn key skills in handling large data and in digital processing of data to acquire competence in digital data analysis; and 4) To acquisition of key competency in scientific writing and presentation. For more information, please visit: <http://www.easl.eu/discover/events/detail/2019/metabolism-immunity-and-liver-disease>.

June 2019 American transplant congress June 1-5, 2019; Hynes Convention Center, Boston, Massachusetts, USA

The American Transplant Congress is designed for physicians, surgeons, scientists, nurses, organ procurement personnel and pharmacists who are interested in the clinical and research aspects of solid organ and tissue transplantation. The meeting will provide the most current information in the field of transplant science. The purpose of the meeting is to: 1) Review and evaluate the latest clinical and basic science advances in transplantation science, medicine and surgery; 2) Investigate recent developments in transplant biology, immunology and organ preservation; 3) Examine the broad but critical issues in transplantation, including social and policy issues. For more information, please visit: <http://www.atcmeeting.org>.

(doi: 10.1016/S1499-3872(19)30018-9)